Immune response induced by live attenuated varicella vaccine and short term follow-up on immunity of the vaccinated children.
Live attenuated varicella vaccine (Oka strain, 500 to 750 PFU) was inoculated into 234 children with various underlying diseases. Varicella-zoster virus (VZV) specific immune adherence hemagglutination antibody developed in 95% of initially seronegative subjects. VZV specific cellular immune responses were detected in 91% of subjects within 6 weeks after vaccination. A preliminary survey of 46 vaccinated normal-risk subjects during the first and the third year revealed excellent protection with the exception of one case who had not shown any antibody response at the fourth week.
D000914:Antibodies, Viral / Q000096:biosynthesis; D002644:Chickenpox / Q000276:immunology* / Q000517:prevention & control; D002648:Child; D002675:Child, Preschool; D003428:Cross Infection / Q000517:prevention & control; D005500:Follow-Up Studies; D006386:Hemagglutination Tests; D014645:Herpesvirus 3, Human / Q000276:immunology*; D006801:Humans; D007109:Immunity; D007165:Immunosuppression Therapy; D007938:Leukemia / Q000276:immunology / Q000628:therapy; D008213:Lymphocyte Activation; D014613:Vaccines, Attenuated / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology*
D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D014765:Viral Vaccines